LBRX
HEALTHCARELB Pharmaceuticals Inc
$32.00-0.88 (-2.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LBRX Today?
No stock-specific AI insight has been generated for LBRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$13.36$33.47
$32.00
Fundamentals
Market Cap$918M
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume218K
Avg Volume (10D)—
Shares Outstanding28.7M
LBRX News
20 articles- LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in SchizophreniaYahoo Finance·Apr 22, 2026
- LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at NeedhamMarketbeat·Apr 17, 2026
- LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 9, 2026
- LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)Yahoo Finance·Mar 27, 2026
- LB Pharmaceuticals Inc.: Q4 Earnings SnapshotYahoo Finance·Mar 26, 2026
- LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 26, 2026
- LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with SchizophreniaYahoo Finance·Mar 25, 2026
- LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029Marketbeat·Mar 20, 2026
- Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsightYahoo Finance·Mar 11, 2026
- LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of DirectorsYahoo Finance·Mar 9, 2026
- LB Pharmaceuticals to Participate in Upcoming March Investor EventsYahoo Finance·Mar 4, 2026
- LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Feb 10, 2026
- LB Pharmaceuticals Announces $100.0 Million Private PlacementYahoo Finance·Feb 5, 2026
- LB Pharmaceuticals initiates Phase 2 trial of LB-102Yahoo Finance·Jan 27, 2026
- LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development ProgramYahoo Finance·Jan 26, 2026
- LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General CounselYahoo Finance·Jan 21, 2026
- LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & CultureYahoo Finance·Jan 6, 2026
- LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® IndicesYahoo Finance·Dec 9, 2025
- LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare ConferenceYahoo Finance·Nov 24, 2025
- LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial OfficerYahoo Finance·Nov 12, 2025
All 20 articles loaded
Price Data
Open$31.61
Previous Close$32.88
Day High$32.26
Day Low$30.89
52 Week High$33.47
52 Week Low$13.36
52-Week Range
$13.36$33.47
$32.00
Fundamentals
Market Cap$918M
P/E Ratio—
EPS$-3.13
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume218K
Avg Volume (10D)—
Shares Outstanding28.7M
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—